Liposomal encapsulated anti-cancer drugs

被引：259

作者：

Hofheinz, RD

Gnad-Vogt, SU

Beyer, U

Hochhaus, A

机构：

[1] Heidelberg Univ, Fak Klin Med Mannheim, Med Klin 3, Onkol Zentrum, D-68167 Mannheim, Germany

[2] Medac GMBH, Wedel, Germany

来源：

ANTI-CANCER DRUGS | 2005年 / 16卷 / 07期

关键词：

D O I：

10.1097/01.cad.0000167902.53039.5a

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Among several drug delivery systems, liposomal encapsulated anti-cancer agents represent an advanced and versatile technology. Several formulations of liposomal anthracyclines are approved, e.g. for the treatment of metastatic breast cancer (pegylated and non-pegylated liposomal doxorubicin) or AIDS-related Kaposi's sarcoma (pegylated liposomal doxorubicin and liposomal daunorubicin). Meanwhile, virtually all anti-cancer drugs have been encapsulated in liposomes using different technologies. This review will summarize preclinical and clinical data of approved and exemplary emerging liposomal anticancer agents.

引用

收藏

页码：691 / 707

页数：17

相关论文

共 127 条

[31] Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily X 5 intravenous administration [J].

Gerrits, CJH ;

Creemers, GJ ;

Schellens, JHM ;

Wissel, P ;

Planting, AST ;

Kunka, R ;

Selinger, K ;

deBoerDennert, M ;

Marijnen, Y ;

Harteveld, M ;

Verweij, J .

BRITISH JOURNAL OF CANCER, 1996, 73 (06) :744-750

[32] Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia [J].

Giles, FJ ;

Tallman, MS ;

Garcia-Manero, G ;

Cortes, JE ;

Thomas, DA ;

Wierda, WG ;

Verstovsek, S ;

Hamilton, M ;

Barrett, E ;

Albitar, M ;

Kantarjian, HM .

CANCER, 2004, 100 (07) :1449-1458

[33] Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma [J].

Gill, PS ;

Wernz, J ;

Scadden, DT ;

Cohen, P ;

Mukwaya, GM ;

vonRoenn, JH ;

Jacobs, M ;

Kempin, S ;

Silverberg, I ;

Gonzales, G ;

Rarick, MU ;

Myers, AM ;

Shepherd, F ;

Sawka, C ;

Pike, MC ;

Ross, ME .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (08) :2353-2364

[34] Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis [J].

Glantz, MJ ;

LaFollette, S ;

Jaeckle, KA ;

Shapiro, W ;

Swinnen, L ;

Rozental, JR ;

Phuphanich, S ;

Rogers, LR ;

Gutheil, JC ;

Batchelor, T ;

Lyter, D ;

Chamberlain, M ;

Maria, BL ;

Schiffer, C ;

Bashir, R ;

Thomas, D ;

Cowens, W ;

Howell, SB .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3110-3116

[35]

Glantz MJ, 1999, CLIN CANCER RES, V5, P3394

[36] Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer [J].

Gordon, AN ;

Tonda, M ;

Sun, S ;

Rackoff, W .

GYNECOLOGIC ONCOLOGY, 2004, 95 (01) :1-8

[37] Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan [J].

Gordon, AN ;

Fleagle, JT ;

Guthrie, D ;

Parkin, DE ;

Gore, ME ;

Lacave, AJ .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) :3312-3322

[38]

GRIEBEL J, 2004, ROFO FORTSCH GEB RON, V176, pP164

[39] Liposomes as vehicles for targeted therapy of cancer. Part 1: Preclinical development [J].

Harrington, KJ ;

Lewanski, CR ;

Stewart, JSW .

CLINICAL ONCOLOGY, 2000, 12 (01) :2-15

[40] Phase I-II study of pegylated liposomal cisplatin (SPI-077™) in patients with inoperable head and neck cancer [J].

Harrington, KJ ;

Lewanski, CR ;

Northcote, AD ;

Whittaker, J ;

Wellbank, H ;

Vile, RG ;

Peters, AM ;

Stewart, JSW .

ANNALS OF ONCOLOGY, 2001, 12 (04) :493-496

← 1 2 3 4 5 6 7 8 9 10 →